X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/everyone-wants-in-on-glp-1-pfizer-doses-first-patient-in-phii-trial-for-diabetes-and-obesity-drug-pays-sosei-10m/
https://www.globenewswire.com/news-release/2022/12/21/2577552/0/en/Sosei-Heptares-Partner-Pfizer-Progresses-its-Oral-GLP-1-Receptor-Agonist-PF-07081532-into-Phase-2-Clinical-Trials-for-Treating-Type-2-Diabetes-and-Obesity.html
https://www.fiercebiotech.com/biotech/lilly-pens-730m-biobucks-deal-sosei-heptares-get-gpcr-action
https://www.globenewswire.com/news-release/2022/11/11/2553973/0/en/Sosei-Heptares-Operational-Highlights-and-Consolidated-Results-for-the-Third-Quarter-and-First-Nine-Months-of-2022.html
https://www.globenewswire.com/news-release/2022/11/09/2551622/0/en/Sosei-Heptares-President-CEO-and-Head-of-UK-R-D-to-Participate-in-a-Fireside-Chat-at-the-Jefferies-London-Healthcare-Conference-2022.html
https://www.globenewswire.com/news-release/2022/10/27/2543501/0/en/Sosei-Heptares-Partner-Neurocrine-Biosciences-Initiates-Phase-2-Clinical-Study-Evaluating-NBI-1117568-in-Adults-with-Schizophrenia.html
https://www.globenewswire.com/news-release/2022/08/10/2495485/0/en/Sosei-Heptares-Operational-Highlights-and-Consolidated-Results-for-the-Second-Quarter-and-First-Half-of-2022.html
https://www.globenewswire.com/news-release/2022/08/04/2492935/0/en/Sosei-Heptares-Oral-Selective-M4-Receptor-Agonist-Advancing-into-Phase-2-Clinical-Development-under-Multi-Program-Collaboration-with-Neurocrine-Biosciences.html
https://pharmaphorum.com/news/abbvie-taps-sosei-heptares-gpcr-expertise-with-1-2bn-alliance/
https://endpts.com/sosei-heptares-partners-with-a-uk-based-cancer-research-organization-to-bring-its-drug-to-trial/
Market Place
Share 
